Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- “Advancements in Domestic Business is Growth Driver” for Achieving Midterm Business Plan : MTPC President Tsuchiya
September 4, 2012
- Ono Ties Up with BioFocus of the UK for Drug Discovery for CNS Disorders
September 4, 2012
- Meiji Seika Pharma Launches COPD Treatment Oxis, Detailed by More Than 600 MRs
September 4, 2012
- Otsuka Applies for Abilify as Adjunctive Therapy for Depression; First Indication for Antipsychotic Drug in Japan
September 4, 2012
- MTPC to Double Number of Vaccine-Specialized MRs to 50, Eyeing TETRABIK Launch
September 3, 2012
- DSP’s US Subsidiary Sunovion to Acquire Elevation Pharmaceuticals of the US
September 3, 2012
- Shionogi to Embark on Collaborative R&D with 5 Danish Universities
September 3, 2012
- MTPC and Nipro Agree on Dissolution of Joint Venture Bipha
September 3, 2012
- 9 Companies Jointly Apply for Combination Use of 3 Agents for H. Pylori Eradication
September 3, 2012
- Wholesalers and Pharmacies See Contrasting Results in 1st Quarter – Which Side Will Come Out the Winner from Non-yieldable Price Bargaining?
September 3, 2012
- Sosei Committed to Becoming a Japan-Based Global Biopharma: Vice President Akihiro Matsuura
September 3, 2012
- Pfizer Japan Launches RCC Treatment Inlyta
August 31, 2012
- Takeda to Conduct Joint Research with Canadian Institute at Shonan Research Center
August 31, 2012
- Eisai Files NDA for Rufinamide for LGS
August 31, 2012
- Novartis to File for COPD Treatment QVA149 in Japan, EU by End of 2012
August 31, 2012
- Kyowa Kirin Temporarily Suspends Patient Enrollment for PIII Study of Its Anticancer Agent ARQ197 Due to ADR
August 31, 2012
- Ribomic Aims to Commercialize Non-Addictive Analgesic Nucleic Acid Drug
August 30, 2012
- Takeda to Start Local Manufacturing at New Russian Factory around FY2014
August 30, 2012
- IBL, IBR to Codevelop Vaccines Using Transgenic Silkworms
August 30, 2012
- Torii to Exclusively Market JT’s Novel Anti-HIV Drug in Japan
August 30, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…